Dr Brawer will assist GTx chief medical officer Ronald Morton, Jr, and vice president of medical affairs Shontelle Dodson in educating the medical community about disease states of interest to GTx and will also participate in the development and execution of clinical research.
Dr Brawer joins GTx from Tokai Pharmaceuticals, where he served as chief medical officer since 2008. From 2006-2007, Dr Brawer was interim chief medical officer at Threshold Pharmaceuticals.
Mitchell Steiner, CEO of GTx, said: “With Michael Brawer’s appointment, GTx continues to build on its well established strength in urology. Dr Brawer is a unique addition to GTx. He brings to GTx his experiences as an entrepreneur, a pharmaceutical executive, a practicing community urologist, and a leading academic physician engaged in basic and clinical research.”